Mankind Pharma Ltd. (IN:MANKIND)
:MANKIND
Want to see IN:MANKIND full AI Analyst Report?
Top Page
Mankind Pharma Ltd.
(MANKIND)
Select Model
Select Model
Rating:68Neutral
Price Target:
₹2,816.00
▲(27.85% Upside)
Action:Reiterated
Date:05/21/26
The score is driven mainly by solid financial performance (consistent growth and healthy margins, with improving leverage) and strong technical momentum (price above major moving averages). These positives are moderated by elevated valuation (high P/E) and recent profitability/cash-conversion pressures (margin compression and weaker operating cash flow relative to earnings).
Positive Factors
Consistent Revenue Growth
Multi-year, consistent revenue growth demonstrates durable demand, effective field-force distribution and brand traction in domestic prescription and OTC markets. This predictability supports capacity planning, reinvestment in brands and R&D, and underpins medium-term earnings visibility.
Negative Factors
Margin Compression
Notable year-over-year margin contraction suggests rising input costs, pricing pressure or adverse product mix. If structural, continued compression will erode free cash flow and ROE, forcing tougher allocation choices and potentially weakening long-term competitive investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
Multi-year, consistent revenue growth demonstrates durable demand, effective field-force distribution and brand traction in domestic prescription and OTC markets. This predictability supports capacity planning, reinvestment in brands and R&D, and underpins medium-term earnings visibility.
Read all positive factors
Mankind Pharma Ltd. (MANKIND) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.07T
Dividend Yield0.04%
Average Volume (3M)10.08K
Price to Earnings (P/E)55.5
Beta (1Y)0.49
Revenue Growth16.27%
EPS Growth-6.07%
CountryIN
Employees19,540
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)42.77
Shares Outstanding412,828,340
10 Day Avg. Volume5,924
30 Day Avg. Volume10,081
Financial Highlights & Ratios
PEG Ratio-7.55
Price to Book (P/B)5.08
Price to Sales (P/S)5.80
P/FCF Ratio43.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹2,820.00Price Target Upside28.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)55.75
Revenue Forecast (FY)₹159.34B
Mankind Pharma Ltd. Business Overview & Revenue Model
Company Description
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of...
How the Company Makes Money
Mankind Pharma primarily makes money by selling pharmaceutical and consumer healthcare products. Its core revenue stream is the sale of branded formulations in India through its domestic distribution and field-force-driven marketing model, where p...
Mankind Pharma Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
66
Positive
Cash Flow
73
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 134.74B | 142.78B | 122.07B | 102.59B | 87.49B | 77.82B |
| Gross Profit | 84.33B | 61.55B | 86.38B | 70.02B | 57.87B | 53.12B |
| EBITDA | 37.54B | 36.17B | 35.58B | 28.04B | 20.37B | 21.97B |
| Net Income | 17.51B | 19.13B | 19.91B | 19.13B | 12.82B | 14.33B |
Balance Sheet | ||||||
| Total Assets | 288.13B | 280.80B | 277.60B | 119.63B | 97.15B | 91.48B |
| Cash, Cash Equivalents and Short-Term Investments | 31.05B | 20.20B | 22.45B | 34.56B | 15.29B | 12.79B |
| Total Debt | 83.69B | 63.12B | 85.11B | 2.07B | 1.70B | 8.73B |
| Total Liabilities | 132.85B | 115.18B | 131.91B | 23.87B | 20.67B | 28.31B |
| Stockholders Equity | 152.86B | 163.00B | 143.32B | 93.63B | 74.35B | 61.55B |
Cash Flow | ||||||
| Free Cash Flow | 13.66B | 18.90B | 19.53B | 17.70B | 9.53B | -14.26B |
| Operating Cash Flow | 16.37B | 25.16B | 24.13B | 21.52B | 17.85B | 9.20B |
| Investing Cash Flow | -11.68B | -2.54B | -126.92B | -20.82B | -10.54B | -13.69B |
| Financing Cash Flow | -5.49B | -22.89B | 102.33B | 52.66M | -7.40B | 6.05B |
Mankind Pharma Ltd. Technical Analysis
Positive
2202.55
Price Trends
2192.68
Positive
2168.94
Positive
2295.38
Positive
Market Momentum
91.97
Negative
71.63
Negative
82.01
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MANKIND, the sentiment is Positive. The current price of 2202.55 is below the 20-day moving average (MA) of 2349.13, above the 50-day MA of 2192.68, and below the 200-day MA of 2295.38, indicating a bullish trend. The MACD of 91.97 indicates Negative momentum. The RSI at 71.63 is Negative, neither overbought nor oversold. The STOCH value of 82.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:MANKIND.
Mankind Pharma Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹1.04T | 19.82 | ― | 0.57% | 23.12% | 62.27% | |
72 Outperform | ₹650.28B | 25.97 | ― | 0.80% | 11.73% | 10.02% | |
71 Outperform | ₹4.51T | 30.62 | ― | 0.91% | 10.09% | -4.53% | |
68 Neutral | ₹1.07T | 55.46 | ― | 0.04% | 16.27% | -6.07% | |
66 Neutral | ₹1.50T | 51.30 | ― | 0.84% | 12.74% | 22.02% | |
64 Neutral | ₹1.05T | 22.07 | ― | 1.19% | 16.81% | 11.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:MANKIND
Mankind Pharma Ltd.
2,583.35
51.30
2.03%
IN:ALKEM
Alkem Laboratories Ltd.
5,438.70
113.32
2.13%
IN:LUPIN
Lupin Limited
2,283.40
300.02
15.13%
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,880.50
165.72
9.66%
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
4,429.85
1,170.13
35.90%
IN:ZYDUSLIFE
Zydus Lifesciences Limited
1,040.95
161.28
18.33%
Mankind Pharma Ltd. Corporate Events
Mankind Pharma Secures High CARE Ratings for ₹1,000 Crore Bank Facilities
Apr 22, 2026
Mankind Pharma Limited has announced that CARE Ratings Limited has newly assigned high credit ratings to the company’s bank facilities, with long-term facilities rated CARE AA+ with a Stable outlook and short-term facilities rated CARE A1+. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.